X4 Pharmaceuticals Completes Public Offering, Securing $155.3 Million with Full Exercise of Underwriters' Option for Additional Shares

Public Offering Announcement: X4 Pharmaceuticals closed an underwritten public offering of 52,844,000 shares of common stock, raising approximately $155.3 million before expenses, with a share price of $2.90.

Warrants and Shares: The offering included pre-funded warrants for 700,000 shares at a price of $2.899, with an exercise price of $0.001, and resulted in a total of 79,214,708 shares outstanding post-offering.

Management and Registration: Leerink Partners, Stifel, and Guggenheim Securities served as joint bookrunning managers, and the offering was conducted under a shelf registration statement effective since August 2023.

Company Focus: X4 Pharmaceuticals is dedicated to developing therapies for rare hematology diseases, with its lead product, mavorixafor, currently marketed as XOLREMDI® and undergoing further clinical trials.